US terms Ecstasy as 'Breakthrough Therapy' in PTSD treatment
The US Food and Drug Administration has designated MDMA, also known as Ecstasy, a 'Breakthrough Therapy' in the treatment of post-traumatic stress disorder (PTSD), approving trials for 200-300 participants. In previous trials, 107 PTSD patients were treated using MDMA-assisted psychotherapy, 61% of whom were cured within two months, said the Multidisciplinary Association for Psychedelic Studies.